相关临床试验
3
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2011
进行中（未招募）
1
33.3%
尚未招募
1
33.3%
暂停
1
33.3%
暂无批准数据
- Halia Therapeutics announced final Phase 2 results for ofirnoflast (HT-6184) showing 67% hematological improvement rate in 30 evaluable patients with lower-risk myelodysplastic syndrome. - The first-in-class NEK7 inhibitor demonstrated 55% transfusion independence for at least 8 weeks among transfusion-dependent patients, with median duration of 28.5 weeks. - The trial reported no treatment-related serious adverse events, with treatment-related adverse events occurring in only 27% of patients. - The company appointed Han Myint, MD, FACP, as Chief Medical Officer to lead clinical development as ofirnoflast advances toward pivotal trials.
- NexImmune's lead candidate NEX-ILE12, a novel interleukin-12 immunomodulator, has shown promising safety profiles and immune activation signals in Phase 1 trials for solid tumors. - The company reported dose-escalation progress without dose-limiting toxicities and plans to initiate combination studies with PD-1 inhibitors by mid-2026. - NexImmune's proprietary Artificial Immune Modulation (AIM) technology differentiates the company by mimicking natural immune synapses, potentially improving efficacy over existing CAR-T approaches. - The company maintains a cash position supporting operations into 2027, though high R&D expenses and potential dilution from future raises remain concerns for investors.
- Vicero, a preclinical biopharmaceutical company, has appointed Dr. Han Myint as Chief Medical Officer to lead clinical strategy for its VINCOBODY immunotherapy portfolio. - Dr. Myint brings over 30 years of experience in oncology drug development, including roles at NextCure, NexImmune, and Celgene/Bristol Myers Squibb. - His immediate focus will be advancing VCR-036, a bispecific PD-1 + CTLA-4 program, into clinical trials with the goal of achieving combination efficacy while reducing immune-related toxicities.
